72814-84-7

Basic information

• Product Name: ERYTHROSIN B ISOTHIOCYANATE, ISOMER II
• Synonyms: ERYTHROSIN B ISOTHIOCYANATE, ISOMER II;ERYTHROSIN ISOTHIOCYANATE;EITC;EITC Erythrosin Isothiocyanate;erythrosin B isothiocyanate
• CAS NO: 72814-84-7
• Molecular Formula: C21H7I4NO5S
• Molecular Weight: 892.97
• Product Categories: E-F;Stains and Dyes;Stains&Dyes, A to;marker
• Mol File: 72814-84-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 710.5°C at 760 mmHg
• Flash Point: 383.5°C
• Appearance: /
• Density: 2.77g/cm³
• Vapor Pressure: 7.34E-21mmHg at 25°C
• Refractive Index: 1.932
• Storage Temp.: Store at 2-8
• PKA: 7.17±0.20(Predicted)
• CAS DataBase Reference: ERYTHROSIN B ISOTHIOCYANATE, ISOMER II(CAS DataBase Reference)
• NIST Chemistry Reference: ERYTHROSIN B ISOTHIOCYANATE, ISOMER II(72814-84-7)
• EPA Substance Registry System: ERYTHROSIN B ISOTHIOCYANATE, ISOMER II(72814-84-7)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 72814-84-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C21H7I4NO5S/c22-12-4-10-18(14(24)16(12)27)30-19-11(5-13(23)17(28)15(19)25)21(10)9-3-7(26-6-32)1-2-8(9)20(29)31-21/h1-5,27-28H

Relevant articles and documents

Single label comparative hybridization

The present invention provides methods of detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, the present invention provides advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.

Substractive single label comparative hybridization

Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities.

Activatable probes and methods for in vivo gene detection

Probes for detecting a target polynucleotide are provided. One aspect provides a molecular beacon probe set wherein the donor molecular beacon comprises a quantum dot and an acceptor molecular beacon comprises at least one reporter. The probes optionally comprise a protein transduction domain, targeting signal, or a combination thereof. Methods for detecting target polynucleotides using the disclosed probes are also provided.